<?xml version="1.0" encoding="UTF-8"?>
<p>AI can help quickly identify potential therapeutics and candidate vaccines. For instance, a collaboration between an AI start-up, BenevolentAI, and a university institution, the Imperial College London, UK, has led to the discovery that baricitinib, a biologic used for the treatment of moderately to severely active rheumatoid arthritis in adults, inhibitor of the janus kinases JAK1 and JAK2, may exert anti-viral effects [
 <xref rid="B24-ijerph-17-03176" ref-type="bibr">24</xref>], whereas another start-up, Insilico Medicine, located in Hong Kong, has reported to have found six new drugs that may inhibit viral replication [
 <xref rid="B14-ijerph-17-03176" ref-type="bibr">14</xref>].
</p>
